Metraipolis › archive › dc_af4a2da3d575
The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental… — Europe PMC PMID:41009577
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41009577
- DOI
- 10.3390/ijms26189010
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T22:21:24.900Z
- SHA-256 of the archived text
a520a1fca55fad83fe372a78f952ad235cc57b40328fc3f63f1d2ef9635e98a1- Stable URL of this page
https://metraipolis.com/documento/dc_af4a2da3d575
How to cite
The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental… — Europe PMC PMID:41009577 — Europe PMC (en), https://europepmc.org/article/MED/41009577 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_af4a2da3d575 (Metraipolis archive dc_af4a2da3d575, sha256 a520a1fca55fad83fe372a78f952ad235cc57b40328fc3f63f1d2ef9635e98a1)
BibTeX
@misc{dcaf4a2da3d575,
title = {The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental… — Europe PMC PMID:41009577},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41009577},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_af4a2da3d575; sha256 a520a1fca55fad83fe372a78f952ad235cc57b40328fc3f63f1d2ef9635e98a1},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41009577. Agents can read the archived copy with the MCP tool read_document.